



BILASTINE IS APPROVED IN TWO OTHER COUNTRIES

Belgium and Lithuania have approved Bilastine's commercialization.

Therefore, there are already ten European countries that have approved Bilastine's commercialization. This fact will strengthen the molecule's international distribution.

Bilastine is a latest generation antihistaminic, with a rapid onset and long lasting action, showing a wide safety profile, indicated for the treatment of allergic rhinoconjunctivitis and urticary.